Optimization of linear and cyclic peptide inhibitors of KEAP1-NRF2 protein-protein interaction.


Journal

Bioorganic & medicinal chemistry
ISSN: 1464-3391
Titre abrégé: Bioorg Med Chem
Pays: England
ID NLM: 9413298

Informations de publication

Date de publication:
01 11 2020
Historique:
received: 26 06 2020
revised: 20 08 2020
accepted: 21 08 2020
pubmed: 17 10 2020
medline: 22 6 2021
entrez: 16 10 2020
Statut: ppublish

Résumé

Inhibition of KEAP1-NRF2 protein-protein interaction is considered a promising strategy to selectively and effectively activate NRF2, a transcription factor which is involved in several pathologies such as Huntington's disease (HD). A library of linear peptides based on the NRF2-binding motifs was generated on the nonapeptide lead Ac-LDEETGEFL-NH

Identifiants

pubmed: 33065433
pii: S0968-0896(20)30568-X
doi: 10.1016/j.bmc.2020.115738
pii:
doi:

Substances chimiques

Kelch-Like ECH-Associated Protein 1 0
NF-E2-Related Factor 2 0
Peptides 0
Peptides, Cyclic 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115738

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Stefania Colarusso (S)

Department of Drug Discovery, IRBM Spa, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy. Electronic address: s.colarusso@irbm.com.

Daniele De Simone (D)

Department of Drug Discovery, IRBM Spa, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Tommaso Frattarelli (T)

Department of Drug Discovery, IRBM Spa, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Matteo Andreini (M)

Department of Drug Discovery, IRBM Spa, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Mauro Cerretani (M)

Translational & Discovery Research, IRBM Spa, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Antonino Missineo (A)

Translational & Discovery Research, IRBM Spa, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Daniele Moretti (D)

Translational & Discovery Research, IRBM Spa, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Sara Tambone (S)

Translational & Discovery Research, IRBM Spa, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Georg Kempf (G)

Proteros Biostructures GmbH, Bunsenstraße 7 a, 82152 Planegg, Germany.

Martin Augustin (M)

Proteros Biostructures GmbH, Bunsenstraße 7 a, 82152 Planegg, Germany.

Stefan Steinbacher (S)

Proteros Biostructures GmbH, Bunsenstraße 7 a, 82152 Planegg, Germany.

Ignacio Munoz-Sanjuan (I)

CHDI Management/CHDI Foundation, Los Angeles, CA, United States.

Larry Park (L)

CHDI Management/CHDI Foundation, Los Angeles, CA, United States.

Vincenzo Summa (V)

Department of Drug Discovery, IRBM Spa, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Licia Tomei (L)

Translational & Discovery Research, IRBM Spa, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Alberto Bresciani (A)

Translational & Discovery Research, IRBM Spa, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Celia Dominguez (C)

CHDI Management/CHDI Foundation, Los Angeles, CA, United States. Electronic address: celia.dominguez@chdifoundation.org.

Leticia Toledo-Sherman (L)

Translational & Discovery Research, IRBM Spa, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Elisabetta Bianchi (E)

Department of Drug Discovery, IRBM Spa, Via Pontina km 30.600, 00071 Pomezia, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH